What the First Factor XIa Approval Means for Developers

On November 9, 2026, the FDA approved Sunharbo (asundexian) 50-mg tablets, making it the first factor XIa inhibitor approved in the US.¹ The once-daily oral therapy from Bayer Pharmaceuticals is indicated in combination with antiplatelet therapy to reduce stroke risk in adults following a recent mild-to-moderate noncardioembolic ischemic stroke—a stroke caused by a clot that did not originate in the heart—or a high-risk transient ischemic attack (TIA).

“Stroke is a leading cause of disability and death in the United States, and survivors are at risk of having another stroke,” said Hylton Joffe, MD, MMSc, director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology, CDER, in a press release.¹ “Today’s approval represents a meaningful advance for patients and health care providers seeking a new option for secondary stroke prevention.”

What Did the Phase 3 Data Show?

The approval rests on OCEANIC-STROKE, a multicenter, randomized, double-blind, placebo-controlled phase 3 study that enrolled 12,327 adults with a recent noncardioembolic ischemic stroke or high-risk TIA.^1,2 Participants were randomly assigned to asundexian or placebo within 72 hours of symptom onset, and both groups also received antiplatelet therapy. Over a median treatment duration of 14.2 months, asundexian reduced the risk of ischemic stroke by 26% compared with placebo.

The full results, published in the New England Journal of Medicine in April 2026, shows that 6.2% of asundexian patients had another ischemic stroke vs 8.4% on placebo, and disabling or fatal strokes fell from 3% to 2.1%.² Participants from 37 countries had a mean age of 68 years; 25% were older than 75. “Until now, reducing stroke risk has often been associated with higher bleeding risk. These findings give us hope for a safer way to prevent recurrent strokes,” said Ashkan Shoamanesh, co–principal investigator and senior scientist, Population Health Research Institute.

The safety profile carries qualifiers.² Overall major bleeding was similar between arms but increased with asundexian in patients older than 75 years and during the first 90 days of treatment. Gastrointestinal bleeding was more common with the drug, and diarrhea was the most frequently reported adverse reaction. The FDA granted the application Fast Track and Priority Review designations.¹

Why Does This Approval Matter for the Factor XI Class?

Factor XIa inhibition rests on the hypothesis that blocking this upstream coagulation protein can prevent pathological clots while largely preserving normal hemostasis.¹Bristol Myers Squibb and Johnson & Johnson are pursuing the same mechanism. “Patients at risk for stroke and other thromboembolic events really need drugs that reduce the risk of dangerous clots without increasing their bleeding risk, and targeting factor XIa may open this possibility,” said Clay Johnston, MD, PhD, MPH, chief medical officer, Harbor Health, in a press release.³

The class has not had a clean path.⁴ Bayer stopped an earlier phase 3 trial of asundexian in atrial fibrillation in November 2023 after the drug failed to match apixaban’s efficacy. That helps explain why the new label excludes stroke prevention in patients with atrial fibrillation.¹ For developers advancing milvexian, abelacimab, and other factor XI candidates, this approval sets the first regulatory benchmark for trial design, end points, and labeling in the class.

What Should Development and Manufacturing Teams Watch?

Several label details reflect familiar pharmacology.¹ The label doesn’t recommend using asundexian with drugs that combine P-glycoprotein induction and strong CYP3A4 induction, such as carbamazepine, because they may reduce effectiveness. An earlier clinical pharmacology study found carbamazepine lowered asundexian exposure by approximately 44%.⁵ The drug is not recommended in moderate or severe hepatic impairment and should be withheld at least 24 hours before elective surgery and after thrombolysis.

With a recent Orzeyful approval, labeled CYP3A4 interactions show how central drug-interaction data become once a novel mechanism reaches market.⁶ For asundexian, interaction management, age-related bleeding risk, and long-term daily dosing in a large secondary-prevention population will shape postmarketing safety monitoring and commercial supply planning.

References

1. FDA. FDA approves first factor XIa inhibitor to help prevent stroke in certain adults at high risk. News release. November 9, 2026. Accessed November 10, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk
2. Population Health Research Institute. New anti-clotting medication lowers risk of stroke without added bleeding. April 16, 2026. Accessed November 10, 2026. https://www.phri.ca/oceanic-stroke/
3. Bristol Myers Squibb. Bristol Myers Squibb introduces “Change the target. change what’s possible.” to highlight unmet needs in cardiovascular and thromboembolic care. News release. February 3, 2026. Accessed November 10, 2026. https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Introduces-Change-the-Target--Change-Whats-Possible--to-Highlight-Unmet-Needs-in-Cardiovascular-and-Thromboembolic-Care/default.aspx
4. Bayer. OCEANIC-AF study stopped early due to lack of efficacy. News release. November 19, 2023. Accessed November 10, 2026. https://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-of-efficacy/
5. Kanefendt F, Brase C, Jungmann N, Fricke R, Engelen A, Schmitz S. Pharmacokinetics of asundexian with combined CYP3A and P-gp inhibitors and an inducer: target in vitro and in vivo studies. Br J Clin Pharmacol. 2024;90(4):1036-1049. doi:10.1111/bcp.15981
6. FDA. FDA approves first drug to treat the full range of narcolepsy type 1 symptoms. News release. August 5, 2026. Accessed November 10, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms